Compass Therapeutics (NASDAQ:CMPX – Get Free Report) and HilleVax (NASDAQ:HLVX – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.
Institutional and Insider Ownership
68.4% of Compass Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 30.0% of Compass Therapeutics shares are owned by company insiders. Comparatively, 29.3% of HilleVax shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares Compass Therapeutics and HilleVax’s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Compass Therapeutics | N/A | N/A | -$42.49 million | ($0.34) | -4.62 |
| HilleVax | N/A | N/A | -$123.57 million | ($3.04) | -4.46 |
Analyst Ratings
This is a summary of current ratings and recommmendations for Compass Therapeutics and HilleVax, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Compass Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| HilleVax | 0 | 0 | 3 | 0 | 3.00 |
Compass Therapeutics presently has a consensus price target of $9.00, suggesting a potential upside of 473.25%. HilleVax has a consensus price target of $30.67, suggesting a potential upside of 126.16%. Given Compass Therapeutics’ higher possible upside, equities analysts plainly believe Compass Therapeutics is more favorable than HilleVax.
Profitability
This table compares Compass Therapeutics and HilleVax’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Compass Therapeutics | N/A | -26.07% | -24.49% |
| HilleVax | N/A | -48.17% | -38.05% |
Risk & Volatility
Compass Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
Summary
Compass Therapeutics beats HilleVax on 7 of the 10 factors compared between the two stocks.
About Compass Therapeutics
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
About HilleVax
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
